Neurochem’s Alzhemed for treatment of Alzheimer’s

On July 18, 2004, Neurochem Inc. released interim data pertaining to a Phase II open-label extension study of the effects of Alzhemed on cognitive function and global measure of performance in patients with mild-to-moderate Alzheimer’s Disease. According to Neurochem, the study showed that approximately 70% of the mild AD patients had stabilized or improved cognitive [...]

Xenova Group’s TA-NIC for the Treatment of Nicotine Addiction

On July 14, 2004 Xenova Group plc released results of a second clinical trial with TA-NIC, a therapeutic vaccine under development for the treatment of nicotine addiction. The company reported that this randomized, placebo controlled, double-blinded study involved a total of 60 smokers and was designed to prove safety and tolerability data while measuring anti-nicotine [...]

Dexanabinol

On March 15, 2004 Pharmos Corporation announced that it had completed patient enrollment in its pivotal Phase III study of dexanabinol for the treatment of severe traumatic brain injury (TBI). A total of 86 trauma centers recruited 860 patients. Pharmos expects to unblind the study data and announce initial results toward the end of this [...]